Patents by Inventor Benjamin Oshlack

Benjamin Oshlack has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
    Patent number: 9808453
    Abstract: Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic, an opioid antagonist and one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: November 7, 2017
    Assignees: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventors: Benjamin Oshlack, Curtis Wright, Christopher Breder
  • Tamper resistant oral opioid agonist formulations
    Patent number: 9801828
    Abstract: Oral dosage forms containing an opioid antagonist in a sequestered form are described. The opioid antagonist is sequestered such that it is not released or substantially not released in the gastrointestinal tract from the dosage form which is administered orally intact. However, when the dosage form is chewed, crushed, heated or dissolved in a solvent, and then administered orally, intranasally, parenterally or sublingually, the opioid antagonist is released and at least partially blocks effects of the opioid agonist.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: October 31, 2017
    Assignee: Purdue Pharma L.P.
    Inventors: Benjamin Oshlack, Curtis Wright, J. David Haddox
  • Pharmaceutical Formulation Containing Gelling Agent
    Publication number: 20170296533
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Application
    Filed: June 29, 2017
    Publication date: October 19, 2017
    Applicants: The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Pharmaceutical formulation containing gelling agent
    Patent number: 9757341
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: September 12, 2017
    Assignees: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Oxycodone formulations
    Patent number: 9750736
    Abstract: The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C24/Cmax oxycodone ratio of 0.6 to 1.0 or 0.7 to 1 after oral administration at steady state to patients and methods thereof.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: September 5, 2017
    Assignee: Purdue Pharma L.P.
    Inventors: Benjamin Oshlack, Curtis Wright, Derek Prater
  • Pharmaceutical formulation containing gelling agent
    Patent number: 9693961
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: July 4, 2017
    Assignees: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Methods of providing analgesia
    Patent number: 9682077
    Abstract: A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: June 20, 2017
    Assignee: PURDUE PHARMA L.P.
    Inventors: Benjamin Oshlack, Hua-Pin Huang, John K Masselink, Alfred Tonelli
  • Methods of providing analgesia
    Patent number: 9675611
    Abstract: A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C12/Cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: June 13, 2017
    Assignee: Purdue Pharma L.P.
    Inventors: Benjamin Oshlack, Hua-Pin Huang, John Masselink, Alfred Tonelli
  • PHARMACEUTICAL FORMULATION CONTAINING OPIOID AGONIST, OPIOID ANTAGONIST AND GELLING AGENT
    Publication number: 20170157115
    Abstract: Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic, an opioid antagonist and one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid.
    Type: Application
    Filed: December 19, 2016
    Publication date: June 8, 2017
    Inventors: Benjamin Oshlack, Curtis Wright, Christopher Breder
  • Controlled release hydrocodone formulations
    Patent number: 9669024
    Abstract: A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C12/Cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: June 6, 2017
    Assignee: Purdue Pharma L.P.
    Inventors: Benjamin Oshlack, Hua-Pin Huang, John Masselink, Alfred Tonelli
  • Controlled release hydrocodone formulations
    Patent number: 9669023
    Abstract: A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: June 6, 2017
    Assignee: PURDUE PHARMA L.P.
    Inventors: Benjamin Oshlack, Hua-Pin Huang, John K Masselink, Alfred Tonelli
  • Controlled release hydrocodone formulations
    Patent number: 9669022
    Abstract: A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C12/Cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: June 6, 2017
    Assignee: Purdue Pharma L.P.
    Inventors: Benjamin Oshlack, Hua-Pin Huang, John Masselink, Alfred Tonelli
  • METHODS OF MANUFACTURING ORAL FORMULATIONS
    Publication number: 20170151229
    Abstract: A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.
    Type: Application
    Filed: December 13, 2016
    Publication date: June 1, 2017
    Inventors: Benjamin Oshlack, Hua-Pin Huang, John K. Masselink, Alfred Tonelli
  • METHODS OF PROVIDING ANALGESIA
    Publication number: 20170143697
    Abstract: A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C12/Cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.
    Type: Application
    Filed: December 13, 2016
    Publication date: May 25, 2017
    Inventors: Benjamin Oshlack, Hua-Pin Huang, John Masselink, Alfred Tonelli
  • Once-a-day oxycodone formulations
    Patent number: 9655893
    Abstract: The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C24/Cmax oxycodone ratio of 0.6 to 1.0 or 0.7 to 1 after oral administration at steady state to patients and methods thereof.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: May 23, 2017
    Assignee: Purdue Pharma L.P.
    Inventors: Benjamin Oshlack, Curtis Wright, Derek Prater
  • Once-A day oxycodone formulations
    Patent number: 9655894
    Abstract: The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C24/Cmax oxycodone ratio of 0.6 to 1.0 or 0.7 to 1 after oral administration at steady state to patients and methods thereof.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: May 23, 2017
    Assignee: Purdue Pharma L.P.
    Inventors: Benjamin Oshlack, Curtis Wright, Derek Prater
  • METHODS OF MANUFACTURING ORAL DOSAGE FORMS
    Publication number: 20170136006
    Abstract: A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C12/Cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.
    Type: Application
    Filed: December 13, 2016
    Publication date: May 18, 2017
    Inventors: Benjamin Oshlack, Hua-Pin Huang, John Masselink, Alfred Tonelli
  • TAMPER RESISTANT DOSAGE FORM COMPRISING CO-EXTRUDED, ADVERSE AGENT PARTICLES AND PROCESS OF MAKING SAME
    Publication number: 20170135959
    Abstract: The present invention relates to co-extruded pharmaceutical compositions and dosage forms comprising an adverse agent, such as an opioid antagonist, which can be sequestered. The pharmaceutical compositions and dosage forms diversion of a dosage form containing an active pharmaceutical agent, such as an opioid. The present invention also relates to methods of treating a patient with such a dosage form, as well as kits containing such a dosage form with instructions for using the dosage form to treat a patient. The present invention further relates to a process for the preparation of such pharmaceutical compositions and dosage forms comprising co-extrusion of a core comprising an adverse agent and a sheath.
    Type: Application
    Filed: January 30, 2017
    Publication date: May 18, 2017
    Inventors: Benjamin Oshlack, Hua-Pin Huang
  • TAMPER RESISTANT ORAL OPIOID AGONIST FORMULATIONS
    Publication number: 20170119685
    Abstract: Oral dosage forms containing an opioid antagonist in a sequestered form are described. The opioid antagonist is sequestered such that it is not released or substantially not released in the gastrointestinal tract from the dosage form which is administered orally intact. However, when the dosage form is chewed, crushed, heated or dissolved in a solvent, and then administered orally, intranasally, parenterally or sublingually, the opioid antagonist is released and at least partially blocks effects of the opioid agonist.
    Type: Application
    Filed: August 24, 2016
    Publication date: May 4, 2017
    Inventors: Benjamin Oshlack, Curtis Wright, J. David Haddox
  • Pharmaceutical Formulation Containing Gelling Agent
    Publication number: 20170112765
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Application
    Filed: November 8, 2016
    Publication date: April 27, 2017
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder